Prof Federico Innocenti speaks to ecancer about bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients, the results of which were presented at this year’s virtual ENA meeting.
In this interview he first talks about what kind of cancers bevacizumab is used against. He then explains the rationale behind carrying out this study.
This analysis incorporated a study of more than 1000 patients who used bevacizumab and Prof Innocenti explains how the statistical analysis was carried out for this study.
In the end, he talks about the key results obtained from this analysis and how these results can change the future use of this drug.